Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia

A meta-analysis

Anthony O. Ahmed, Andrew M. Mantini, Daniel J. Fridberg, Peter F Buckley

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Studies suggest that the BDNF Val66Met (rs6265) polymorphism is associated with the incidence of schizophrenia and neurocognitive functioning. These associations appear to be however somewhat mixed. We conducted two separate meta-analyses to investigate (1) the association between the Val66Met polymorphism and neurocognition in people with schizophrenia and (2) the association between peripheral expression of BDNF and neurocognitive phenotypes. For the first aim, we identified 12 studies and 67 comparisons of Met allele carriers and Val homozygotes. These comparisons included 1890 people with schizophrenia (men=1465, women=553), of whom 972 were Met allele carriers and 918 were Val homozygotes. For the second aim, we identified five studies and 25 correlations of peripheral BDNF and neurocognitive scores. The meta-analysis for the second aim included 414 people with schizophrenia (men=292, women=170). First, we found non-significant difference between the genotype groups on most neurocognitive domains. Second, correlations between peripheral BDNF and neurocognitive phenotypes were minimal but we obtained significant effects for the reasoning and problem-solving domains; thus, higher levels of BDNF expression corresponded to better performance on reasoning/problem-solving tasks. The meta-analyses did not robustly establish an association between BDNF Val66Met polymorphism and neurocognition in schizophrenia.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalPsychiatry Research
Volume226
Issue number1
DOIs
StatePublished - Mar 30 2015

Fingerprint

Brain-Derived Neurotrophic Factor
Meta-Analysis
Schizophrenia
Homozygote
Alleles
Phenotype
Genotype
Incidence

Keywords

  • BDNF
  • Neurocognition
  • Schizophrenia
  • Val66Met

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia : A meta-analysis. / Ahmed, Anthony O.; Mantini, Andrew M.; Fridberg, Daniel J.; Buckley, Peter F.

In: Psychiatry Research, Vol. 226, No. 1, 30.03.2015, p. 1-13.

Research output: Contribution to journalReview article

Ahmed, Anthony O. ; Mantini, Andrew M. ; Fridberg, Daniel J. ; Buckley, Peter F. / Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia : A meta-analysis. In: Psychiatry Research. 2015 ; Vol. 226, No. 1. pp. 1-13.
@article{8e96405863a74ce3af49a362141b8781,
title = "Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: A meta-analysis",
abstract = "Studies suggest that the BDNF Val66Met (rs6265) polymorphism is associated with the incidence of schizophrenia and neurocognitive functioning. These associations appear to be however somewhat mixed. We conducted two separate meta-analyses to investigate (1) the association between the Val66Met polymorphism and neurocognition in people with schizophrenia and (2) the association between peripheral expression of BDNF and neurocognitive phenotypes. For the first aim, we identified 12 studies and 67 comparisons of Met allele carriers and Val homozygotes. These comparisons included 1890 people with schizophrenia (men=1465, women=553), of whom 972 were Met allele carriers and 918 were Val homozygotes. For the second aim, we identified five studies and 25 correlations of peripheral BDNF and neurocognitive scores. The meta-analysis for the second aim included 414 people with schizophrenia (men=292, women=170). First, we found non-significant difference between the genotype groups on most neurocognitive domains. Second, correlations between peripheral BDNF and neurocognitive phenotypes were minimal but we obtained significant effects for the reasoning and problem-solving domains; thus, higher levels of BDNF expression corresponded to better performance on reasoning/problem-solving tasks. The meta-analyses did not robustly establish an association between BDNF Val66Met polymorphism and neurocognition in schizophrenia.",
keywords = "BDNF, Neurocognition, Schizophrenia, Val66Met",
author = "Ahmed, {Anthony O.} and Mantini, {Andrew M.} and Fridberg, {Daniel J.} and Buckley, {Peter F}",
year = "2015",
month = "3",
day = "30",
doi = "10.1016/j.psychres.2014.12.069",
language = "English (US)",
volume = "226",
pages = "1--13",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia

T2 - A meta-analysis

AU - Ahmed, Anthony O.

AU - Mantini, Andrew M.

AU - Fridberg, Daniel J.

AU - Buckley, Peter F

PY - 2015/3/30

Y1 - 2015/3/30

N2 - Studies suggest that the BDNF Val66Met (rs6265) polymorphism is associated with the incidence of schizophrenia and neurocognitive functioning. These associations appear to be however somewhat mixed. We conducted two separate meta-analyses to investigate (1) the association between the Val66Met polymorphism and neurocognition in people with schizophrenia and (2) the association between peripheral expression of BDNF and neurocognitive phenotypes. For the first aim, we identified 12 studies and 67 comparisons of Met allele carriers and Val homozygotes. These comparisons included 1890 people with schizophrenia (men=1465, women=553), of whom 972 were Met allele carriers and 918 were Val homozygotes. For the second aim, we identified five studies and 25 correlations of peripheral BDNF and neurocognitive scores. The meta-analysis for the second aim included 414 people with schizophrenia (men=292, women=170). First, we found non-significant difference between the genotype groups on most neurocognitive domains. Second, correlations between peripheral BDNF and neurocognitive phenotypes were minimal but we obtained significant effects for the reasoning and problem-solving domains; thus, higher levels of BDNF expression corresponded to better performance on reasoning/problem-solving tasks. The meta-analyses did not robustly establish an association between BDNF Val66Met polymorphism and neurocognition in schizophrenia.

AB - Studies suggest that the BDNF Val66Met (rs6265) polymorphism is associated with the incidence of schizophrenia and neurocognitive functioning. These associations appear to be however somewhat mixed. We conducted two separate meta-analyses to investigate (1) the association between the Val66Met polymorphism and neurocognition in people with schizophrenia and (2) the association between peripheral expression of BDNF and neurocognitive phenotypes. For the first aim, we identified 12 studies and 67 comparisons of Met allele carriers and Val homozygotes. These comparisons included 1890 people with schizophrenia (men=1465, women=553), of whom 972 were Met allele carriers and 918 were Val homozygotes. For the second aim, we identified five studies and 25 correlations of peripheral BDNF and neurocognitive scores. The meta-analysis for the second aim included 414 people with schizophrenia (men=292, women=170). First, we found non-significant difference between the genotype groups on most neurocognitive domains. Second, correlations between peripheral BDNF and neurocognitive phenotypes were minimal but we obtained significant effects for the reasoning and problem-solving domains; thus, higher levels of BDNF expression corresponded to better performance on reasoning/problem-solving tasks. The meta-analyses did not robustly establish an association between BDNF Val66Met polymorphism and neurocognition in schizophrenia.

KW - BDNF

KW - Neurocognition

KW - Schizophrenia

KW - Val66Met

UR - http://www.scopus.com/inward/record.url?scp=84926214776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926214776&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2014.12.069

DO - 10.1016/j.psychres.2014.12.069

M3 - Review article

VL - 226

SP - 1

EP - 13

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -